Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02161861
Other study ID # P071002
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date September 8, 2014
Est. completion date April 2016

Study information

Verified date May 2020
Source Assistance Publique - Hôpitaux de Paris
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

cFEE peptide improves the IVF fertilization rate in mouse and fertilization index in human. It improves sperm movement's parameters.

It has been studied over 3 generations of mice and appears without any side effects. The Agence de la BioMédecine has given the authorization for testing the peptide in human IVF.

It is expected to improve the fertilization rate, and thus provide more embryos per IVF attempt.

160 couples will be included over 15 months. Patient sperm parameters should be suitable for IVF. Female should be between 18 and 43 year old. Each cohort of eggs will be randomly distributed to one of the 2 groups The first group will be inseminated with 100000/ml motile spermatozoa. The second will be similarly inseminated but in a middle which will be supplemented with cFEE 100µM.

Criteria: number of embryos in each group


Description:

Name and address of the coordinating investigator : Prof. Jean Philippe Wolf, Histology - Embryology Department , Biology of Reproduction - . Cochin Hospital , 123 Bd Port Royal, 75014 Paris Promotor: AP- HP represented by DRCD - Hôpital Saint- Louis Inclusion Sites : CHU Cochin, Paris

Main objective:

- To improve fertilization rate in IVF by supplementation of culture media with a molecule increasing the sperm fertilizing ability.

Secondary objectives

- Compare the rates of cleavage between the two groups of zygotes

- Compare the percentage of good quality embryos

Number of patients : 160 Duration of the inclusion period : 15 months Duration of participation of the patient: For each couple, the duration of participation will be as many times nine months that pregnancies will be obtained from fresh or frozen embryo transfers.In the absence of pregnancy duration of participation will be only 15 days.

Time monitoring of children : 9 months

Total study duration : The total study duration will be 36 months

Rational :

The cyclic tripeptide FEEc reproduces the binding site of Fertilin Beta. It binds to the alpha 6 beta 1 integrin and increases sperm fertilizing ability, improving its movement's parameters . Added to insemination IVF media, it should increase fertilization rates .

Methodology:

Oocytes in each cohort will be divided into two groups, one of which will be inseminated with the control medium and the other group is inseminated in the presence of peptide. The fertilization rate and embryo quality will be compared between these two groups.

Statistical analysis:

In mice with healthy gamete, the observed fertilization rate increase in the presence of peptide was 100 %. The fertilization rate in human IVF is about 65%, male indications included. There is an improvement of the fertilization index of zona free human oocytes of about 90% . We can reasonably foresee an improvement of 15 % of the fertilization rate in normal IVF.

This is why we believe that the difference between fertilization rates of both treated and control groups must be meaningful for 160 attempts. In this calculation it was assumed that the intra cluster correlation (ie intra cohort oocyte ) resulted in a 'design effect' D equal to 4.

The analysis will include descriptive statistics for each quantitative parameter at each time : mean, standard deviation , minimum, maximum , median and quartiles , number of missing values . Quality parameters will be expressed by their frequency of distribution and associated 95% bilateral confidence intervals.The distributions of the numbers of blastomeres per embryo will be compared between the two groups by exact permutation test (stratified). This method is more suitable than "naive" comparison of these numbers, since it takes into account the possible correlation between results for embryos belonging to the same embryo cohort (Gibbons JD 1985 Non parametric statistical inference - Marcel Dekker New York ). The cellular index, the pregnancy rate, spontaneous abortions, therapeutic abortion, childbirth, will be compared using Student's t test and exact Fisher test. All tests will be bilateral, and look for possible negative effects, set at 5%. Calculations will be performed using SAS statistical software v9.13 (SAS Institute, Cary , NC) under the supervision of Professor Eric Vicaut URC Lariboisière St. Louis.

Primary endpoint : Rate of fertilization Expected Benefits : Improved fertilization rates of at least 15 %


Recruitment information / eligibility

Status Terminated
Enrollment 66
Est. completion date April 2016
Est. primary completion date October 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years to 43 Years
Eligibility Inclusion Criteria:

- Patients eligible for in vitro fertilization except indication of ICSI. That is to say : the patients whose sperm has the following characteristics :

- Sperm count over 107 spz /ml and Mobility * ( a + b ) is greater than 15 %

- Typical forms above 10%

- Women aged 18 to 43 years.

- Patients gave their informed written consent

- People affiliated to a social security system

Exclusion Criteria:

- Patients whose sperm indicates the use or ICSI

- Patients who have not given their consent or without the consent of one of the two spouses

- Ovarian failure , menopause

Study Design


Related Conditions & MeSH terms


Intervention

Other:
cFFE increase the fusiogenic capacities of a gamete


Locations

Country Name City State
France Wolf Paris

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

References & Publications (4)

Barraud-Lange V, Naud-Barriant N, Ducot B, Chambris S, Bomsel M, Wolf JP, Ziyyat A. Cyclic QDE peptide increases fertilization rates and provides healthy pups in mouse. Fertil Steril. 2009 May;91(5 Suppl):2110-5. doi: 10.1016/j.fertnstert.2008.05.088. Epub 2008 Aug 9. — View Citation

Wolf JP, Bomsel M. Brevet international "Peptide augmentant la capacité fusiogène d'une gamète" Université Paris 13 et CNRS. N° d'enregistrement 03 13545 ; N° de publication 2 862 225. 2003

Yuan R, Primakoff P, Myles DG. A role for the disintegrin domain of cyritestin, a sperm surface protein belonging to the ADAM family, in mouse sperm-egg plasma membrane adhesion and fusion. J Cell Biol. 1997 Apr 7;137(1):105-12. — View Citation

Ziyyat A, Naud-Barriant N, Barraud-Lange V, Chevalier F, Kulski O, Lemkecher T, Bomsel M, Wolf JP. Cyclic FEE peptide increases human gamete fusion and potentiates its RGD-induced inhibition. Hum Reprod. 2005 Dec;20(12):3452-8. Epub 2005 Aug 11. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Fertilization rates 24 hours
Secondary Embryo quality The embryo quality will be assessed according to the number of blastomeres, the presence of cytoplasmic fragments, multinucleated blastomeres, they shape and regularity, and their cleavage rate. Data will be compared to the Z score classification for the zygote, and the Gardner classification for the blastocyste. day 5
Secondary Pregnancy outcome 9 months
Secondary Baby health Baby health will be assessed on data collected during the pregnancy by the OBGYN, the 6 month ultrasound examination, and the health of the baby at delivery. It will consider the APGAR index and its weight and stature. During the first year of life, the baby health will be assessed by the pediatrician's examination at 6 month and one year old. Year one
See also
  Status Clinical Trial Phase
Completed NCT03442582 - Afluria Pregnancy Registry
Not yet recruiting NCT05934318 - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) N/A
Enrolling by invitation NCT05415371 - Persistent Poverty Counties Pregnant Women With Medicaid N/A
Completed NCT04548102 - Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman N/A
Completed NCT03218956 - Protein Requirement During Lactation N/A
Completed NCT02191605 - Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy N/A
Completed NCT02223637 - Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
Recruiting NCT06049953 - Maternal And Infant Antipsychotic Study
Active, not recruiting NCT02577536 - PregSource: Crowdsourcing to Understand Pregnancy
Not yet recruiting NCT04786587 - Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
Not yet recruiting NCT05412238 - Formulation and Evaluation of the Efficacy of Macro- and Micronutrient Sachets on Pregnant Mothers and Children Aged 6-60 Months N/A
Not yet recruiting NCT05028387 - Telemedicine Medical Abortion Service Using the "No-test" Protocol in Ukraine and Uzbekistan.
Completed NCT02683005 - Study of Hepatitis C Treatment During Pregnancy Phase 1
Completed NCT02783170 - Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women Phase 4
Recruiting NCT02564250 - Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women N/A
Recruiting NCT02619188 - Nutritional Markers in Normal and Hyperemesis Pregnancies N/A
Recruiting NCT02507180 - Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
Completed NCT02379728 - Ghana PrenaBelt Trial: A Positional Therapy Device to Reduce Still-Birth N/A
Completed NCT02408315 - Induction With Misoprostol: Oral Mucosa Versus Vaginal Epithelium (IMPROVE) Phase 3
Terminated NCT02546193 - Outpatient Foley Catheter Compared to Usual Inpatient Care for Labor Induction N/A